Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(TSV:NGEN)

3.050 -0.240 (-7.29%)
Streaming Delayed Price Updated: 3:59 PM EDT, Jun 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 218,916
Open 3.110
Bid (Size) 3.000 (20)
Ask (Size) 3.100 (5)
Prev. Close 3.290
Today's Range 2.920 - 3.260
52wk Range 1.650 - 7.050
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
NervGen Pharma Reports Positive Topline Data from the Chronic Cohort of its Phase 1b/2a Clinical Trial Evaluating NVG-291 in Spinal Cord Injury
From NervGen Pharma Corp.
Via GlobeNewswire
Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire

Performance

YTD
-8.1%
-8.1%
1 Month
+2.7%
+2.7%
3 Month
+5.2%
+5.2%
6 Month
+13.8%
+13.8%
1 Year
+45.2%
+45.2%

More News

Read More
Life Sciences Investor Forum Agenda Announced for March 13th
From Virtual Investor Conferences
Via GlobeNewswire
Life Science Investor Forum: Presentations Now Available for Online Viewing
From Virtual Investor Conferences
Via GlobeNewswire
Life Science Investor Forum Agenda Announced for June 22nd
From Virtual Investor Conferences
Via GlobeNewswire
NervGen Pharma Announces Leadership Transition
Via Newsfile
Encode Ideas, L.P. Announces the Initiation of Research Coverage on NervGen Pharma Corp.
Via Newsfile
NervGen Pharma’s NVG-291-R Demonstrates Significant Functional Repair From a Stroke 7 Days After Onset in Landmark Preclinical Study by University of Cincinnati and Case Western Reserve University
From NervGen Pharma Corp.
Via Business Wire
NervGen Engages Vorticom Inc. to Provide Media Relations Services
Via Newsfile
Exposures COVID-19
NervGen Pharma Enters into Research Agreement with Sylics to Study NVG-291 in Alzheimer's Disease Models
Via Newsfile
Exposures COVID-19 Product Safety
NervGen Pharma Reports First Quarter 2021 Results
Via Newsfile
Exposures COVID-19 Product Safety
NervGen Pharma Announces Closing of Overnight Marketed Equity Offering
Via Newsfile
Exposures COVID-19
NervGen Pharma Grants Stock Options
Via Newsfile
NervGen Pharma Announces First Subject Dosed in Phase 1 Clinical Trial of NVG-291
Via Newsfile
Exposures COVID-19
NervGen Pharma Corp. Announces Overnight Marketed Equity Offering
Via Newsfile
Exposures COVID-19
NervGen Pharma Grants Stock Options
Via Newsfile
NervGen Pharma Announces Appointment of Pharma Veteran Dr. Daniel Mikol as Chief Medical Officer
Via Newsfile
Exposures COVID-19 Product Safety
NervGen Pharma Receives Ethics Approval to Initiate Phase 1 Clinical Trial for NVG-291
Via Newsfile
Exposures COVID-19 Product Safety
NervGen Pharma Reports 2020 Year End Results
Via Newsfile
Exposures COVID-19 Product Safety

Frequently Asked Questions

Is NGEN publicly traded?
Yes, NGEN is publicly traded.
What exchange does NGEN trade on?
NGEN trades on the Toronto Venture Stock Exchange
What is the ticker symbol for NGEN?
The ticker symbol for NGEN is NGEN on the Toronto Venture Stock Exchange
What is the current price of NGEN?
The current price of NGEN is 3.050
When was NGEN last traded?
The last trade of NGEN was at 06/05/25 03:59 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.